제품 > 항체 > Biosimilar Antibody

Human Integrin alpha 4 Monoclonal Antibody (YR0128)

Datasheet

Basic Information

CloneNatalizumab Biosimilar
Molecular Weight150 kDa
Endotoxin<1EU/mg (<0.001EU/μg)Determined by LAL gel clotting assay
Sterility0.2 μm filtration
Aggregation<5% Determined by SECP
Purity>95% Determined by SDS-PAGE
ProductionPurified from cell culture supernatant in an animal-free facility
PurificationProtein A or G purification
Storage2 - 8°C for up to 4 weeks and -80°C for long term storage (Avoid repeated freezing and thawing)
Natalizumab is a monoclonal anti-integrin antibody which binds to the alpha 4 subunit of integrins to prevent migration of immune cells, and is used to treat Crohn's disease or multiple sclerosis.Humanized IgG4k monoclonal antibody produced in murine myeloma cells. Natalizumab contains human framework regions and the complementarity-determining regions of a murine antibody that binds to a4-integrin.Binds to the α4-subunit of α4b 1 and α4b 7 integrins expressed on the surface of all leukocytes except neutrophils, and inhibits the α4-mediated adhesion of leukocytes to their counter-receptor(s).
Isotypehuman IgG4 kappa
ImmunogenHuman Integrin alpha 4
RecommendedIsotype Control(s)In Vivo Grade Recombinant Human IgG4-S228P Kappa Isotype Control Antibody
Recommended Dilution Buffer1×PBS pH 7.0

* For research use only. Not for therapeutic or diagnostic purposes.